Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling.
暂无分享,去创建一个
Brian Higgins | Larry Norton | C. Hudis | L. Norton | M. Theodoulou | T. Traina | B. Higgins | K. Kolinsky | Clifford A Hudis | Tiffany A Traina | Maria Theodoulou | Kenneth Kolinsky | Ute Dugan | U. Dugan
[1] L. Norton,et al. Tumor size, sensitivity to therapy, and design of treatment schedules. , 1977, Cancer treatment reports.
[2] L. Norton,et al. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. , 2001, The oncologist.
[3] W. Scheithauer,et al. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] J. Spratt,et al. Mammographic assessment of human breast cancer growth and duration , 1993 .
[5] R. Baynes,et al. High-dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer. , 2000, The oncologist.
[6] E. Perez,et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] D. Wickerham,et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] A. Buzdar,et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] L. Norton. Evolving concepts in the systemic drug therapy of breast cancer. , 1997, Seminars in oncology.
[10] B. Reigner,et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Barbara L. Smith,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] L. Norton,et al. The Norton-Simon hypothesis revisited. , 1986, Cancer treatment reports.
[13] D. Berry,et al. Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG , 2005 .
[14] H. Burger,et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] L. Norton,et al. Predicting the course of Gompertzian growth , 1976, Nature.
[16] M. Piccart-Gebhart. Mathematics and oncology: a match for life? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] D. Berry,et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] B. Reigner,et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] H. Ishitsuka,et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. , 1998, European journal of cancer.
[20] L. Norton,et al. Growth curve of an experimental solid tumor following radiotherapy. , 1977, Journal of the National Cancer Institute.
[21] W. Scheithauer,et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] D. Heimbrook,et al. Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model. , 2007, Anticancer research.
[23] H. Skipper,et al. Kinetics of mammary tumor cell growth and implications for therapy , 1971, Cancer.
[24] G. Bonadonna,et al. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. , 1995, JAMA.
[25] Larry Norton,et al. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. , 2005, The oncologist.
[26] M. Retsky,et al. A stochastic numerical model of breast cancer growth that simulates clinical data. , 1984, Cancer research.
[27] G. Hortobagyi,et al. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] P Kelly Marcom,et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] A. Buzdar,et al. Multicenter, Phase II study of capecitabine in taxane‐pretreated metastatic breast carcinoma patients , 2001, Cancer.
[30] A. J. Valleron,et al. A simulation model of the natural history of human breast cancer. , 1985, British Journal of Cancer.
[31] Larry Norton,et al. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] M. Berger,et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.
[33] J S Spratt,et al. Decelerating growth and human breast cancer , 1993, Cancer.
[34] A. Schindler,et al. Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] L. Norton. A Gompertzian model of human breast cancer growth. , 1988, Cancer research.
[36] Richard L Schilsky,et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] H. Burger,et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.